Effect of an immuno-suppresive medication (cyclosporine) on brain tumor patients survival

Phase 2

• Conditions: glioblastoma multiform.; Malignant neoplasm of brain/unspecified; C71.9

• Registration Number: IRCT201512028612N3
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Age over 18 years
No history of surgery and/or previous chemoteraphy
Confirmed diagnosis of gliobalstoma

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Performance Status (Survival). Timepoint: measured every 2 months after recruitment up to one year. Method of measurement: Karnofsky Performance Status Scale.